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 42 
Abstract 43 
Proliposome formulations containing salbutamol sulphate (SS) were developed using spray drying, 44 
and the effects of carrier type (lactose monohydrate (LMH) or mannitol) and lipid to carrier ratio 45 
were evaluated. The lipid phase comprised soy phosphatidylcholine (SPC) and cholesterol (1:1), and 46 
the ratios of lipid to carrier were 1:2, 1:4, 1:6, 1:8 or 1:10 w/w.  X-ray powder diffraction (XRPD) 47 
revealed an interaction between the components of the proliposome particles, and scanning electron 48 
microscopy (SEM) showed that mannitol-based proliposomes were uniformly sized and spherical, 49 
whilst LMH-based proliposomes were irregular and relatively large. Using a two-stage impinger 50 
(TSI), fine particle fraction (FPF) values of the proliposomes were higher for mannitol-based 51 
formulations, reaching 52.6%, which was attributed to the better flow properties when mannitol was 52 
used as carrier. Following hydration of proliposomes, transmission electron microscopy (TEM) 53 
demonstrated that vesicles generated from mannitol-based formulations were oligolamellar, while 54 
LMH-based proliposomes generated “worm-like” structures and vesicle clusters. Vesicle size 55 
decreased upon increasing carrier to lipid ratio, and the zeta potential values were negative. Drug 56 
entrapment efficiency (EE) was higher for liposomes generated from LMH-based proliposomes, 57 
reaching 37.76% when 1:2 lipid to carrier ratio was used. The in vitro drug release profile was similar 58 
for both carriers when 1:6 lipid to carrier ratio was used. This study showed that spray drying can 59 
produce inhalable proliposome microparticles that can generate liposomes upon contact with an 60 
aqueous phase, and the FPF of proliposomes and the EE offered by liposomes were formulation-61 
dependent.  62 
Key words: Aerosol; Morphology; Particle size; Powder; Pulmonary 63 
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 69 
1. Introduction 70 
Inhalation of therapeutic materials in liposome formulations has been studied as a strategy for 71 
controlled drug release in the lungs. There is evidence that liposomes can retain the drug in the 72 
pulmonary tissues for prolonged periods, reducing the need for frequent dosing and minimizing the 73 
potential of systemic adverse effects (1-5). Many studies have investigated the pulmonary delivery 74 
of relatively large volumes of liposome dispersions using medical nebulizers (1,6,7). There are at 75 
least two nebulizable liposome formulations currently in clinical trials for potential approval in the 76 
treatment of pulmonary infections, for example, Arikace® (liposomal Amikacin) for the treatment of 77 
pseudomonas aeruginosa in cystic fibrosis patients (7,8), and Pulmaquin® (liposomal ciprofloxacin) 78 
for the treatment of non-cystic fibrosis lung infections (9). 79 
Although nebulization is the most studied means of delivering liposomes by inhalation, there are a 80 
number of disadvantages associated with using nebulizers for this purpose. First, liposome instability 81 
caused by shearing during nebulization and concomitant losses of the originally entrapped drug is a 82 
major challenge, necessitating extensive work to engineer the optimal liposome size and bilayer 83 
composition, and select nebulizers with appropriate designs and operating parameters (7,10). Second, 84 
the performance of the aerosol (e.g. output, droplet size, ‘FPF’, etc.) generated from these nebulizers 85 
is greatly influenced by the physicochemical properties of formulation (11,12), which means that 86 
nebulizer performance for one liposome dispersion may not be the same for another formulation (13). 87 
Third, the large volumes delivered via nebulizers may contribute to toxicity not only by the drug but 88 
also by the accompanying excipients. For example, in pulmonary infections, inhalation of relatively 89 
large antibiotic doses is needed to eradicate the infection, necessitating the use of large phospholipid 90 
quantities to entrap the antibiotic and sustain its release. In spite of the established biocompatibility 91 
and biodegradability of liposomes, dose-limiting toxicity of phospholipids in animals has been 92 
reported (14). 93 
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Dry powder inhalers (DPIs) offer the advantages of delivering small doses of drug and excipients, 94 
and avoidance of shearing-induced liposome instability during delivery. Compared to the number of 95 
studies published for the delivery of liquid liposome dispersions via nebulization, a limited number 96 
of reports have attempted to explore the potential of liposomes and phospholipid formulations for 97 
pulmonary applications delivered in the dry powder form. It has been postulated by several 98 
investigators that dried liposomes would exploit the aqueous environment of the lung to be hydrated 99 
in situ within the respiratory tract (5). Freeze-drying of liposomes in the presence of a cryoprotectant 100 
followed by micronization has been studied for the generation of inhalable dry powder liposomes; 101 
however, milling may exert a deleterious effect on vesicle stability, causing leakage of the drug upon 102 
rehydration (15,16). As an alternative to freeze-drying (lyophilization), spray-drying of liposomes 103 
dispersed in carbohydrate solutions has been investigated, with high powder ‘respirability’ being 104 
reported in a range of studies (17-21).  105 
As an alternative to traditional liposome powders, particulate proliposome formulations have been 106 
developed for inhalation. Proliposomes are carbohydrate carriers coated with phospholipid to 107 
generate liposomes upon addition of aqueous phase (22,23). Proliposomes, in the context of this 108 
study, are phospholipid and drug blended with diluent carbohydrate carriers, aiming to generate 109 
liposomes upon contact with the pulmonary physiological milieu (5). In one approach, phospholipid 110 
and drug were mixed with lactose followed by air-jet milling. The resultant proliposome blend 111 
generated multilamellar vesicles (MLVs) upon dispersion in aqueous phase, with entrapment 112 
efficiencies (24) and fine particle fractions (FPF) (25) being dependent on formulation. Spray drying 113 
of alcoholic phospholipid solutions may also generate proliposome particles (26-28) with FPFs in the 114 
range of 20-30% using antibiotics such as pyrazinamide (28). Thus, the potential of inhalable 115 
proliposome powders has been explored for delivering antimicrobial drugs. Although the antibacterial 116 
activity of hydrated proliposome has been established in vitro (27), the need for large doses for the 117 
eradication of lung infections in vivo raises doubts about the suitability of DPIs in delivering 118 
therapeutic amounts of antimicrobial agents. Unlike pulmonary infections, the doses needed to treat 119 
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asthma are very small, hence powdered formulations (e.g. in the form of proliposomes) can 120 
potentially be used as antiasthma delivery systems.  121 
In this study, we have introduced a potentially applicable approach for pulmonary delivery using 122 
spray-dried proliposomes loaded with salbutamol sulphate (SS). Proliposomes consisted of 123 
carbohydrate carriers (lactose monohydrate or mannitol) and lipids (soya phosphatidylcholine and 124 
cholesterol; 1:1) were formulated using a range of lipid to carriers ratios. The resultant proliposome 125 
powders were thoroughly characterized, and using a two-stage impinger (TSI), the deposition of the 126 
drug was evaluated following proliposome delivery from a Monodose inhaler device. Furthermore, 127 
the ability of the proliposomes to generate liposomes following hydration was studied and drug 128 
entrapment was determined, to evaluate the potential of the formulations in providing a reservoir, in 129 
situ, for sustaining the drug release. The findings of this study using proliposomes were evaluated in 130 
light of the progress achieved in the field of pulmonary delivery of dry powder formulations. 131 
 132 
2. Materials and methods 133 
 134 
2.1 Materials 135 
Lactose monohydrate (LMH) was purchased from VWR, UK, and D-mannitol and cholesterol (CH) 136 
were bought from Sigma Aldrich, UK. Solvents used in HPLC experiments including Water and 137 
methanol were HPLC-grade and HPLC-grade 99.9%, respectively and were supplied by Fisher 138 
Scientific, UK. Absolute ethanol and ethanol (96%) were also purchased from Fisher Scientific, UK. 139 
Sodium 1-hexane sulfonate monohydrate (99%), acetic acid glacial (99%) and salbutamol sulphate 140 
(SS; 99%) were purchased from Alfa-Aesar, UK. The phospholipid used, namely soya 141 
phosphatidylcholine (SPC; Lipoid S-100) was kindly gifted by Lipoid, Switzerland.  142 
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2.2 Methods 143 
 144 
2.2.1 Spray drying of mannitol and LMH  145 
Carbohydrate carriers (LMH or mannitol) were spray-dried by dissolving the carrier particles in 146 
distilled water (1% w/v), followed by spraying the carbohydrate solution through the spray-drier’s 147 
nozzle (diameter = 0.7 mm) using a B-290 spray drier (Büchi, Switzerland). The inlet temperature 148 
was set at 130°C, spraying flow rate was 600 L/h, feed rate was 17%, and the outlet temperature was 149 
70 ± 2°C. The resultant spray-dried microparticles were used as core carriers to prepare particulate-150 
based proliposomes. This step of spray drying aimed for enhancing the dispersion of the carbohydrate 151 
carriers in ethanol during the preparation of proliposomes, as described in the subsequent section. 152 
2.2.2 Manufacture of particulate-based proliposome particles via spray drying 153 
The constituents used to prepare proliposomes are demonstrated in Table 1. Spray-dried mannitol or 154 
LMH microparticles were employed as core carriers for manufacturing proliposomes. This was 155 
achieved by weighing a total of 100 mg lipid consisting of SPC and CH (1:1 mole/mole), followed 156 
by addition of 100 mL ethanol (96% grade), and SS (10 mg). The alcoholic mixture was sonicated 157 
for 1 min to aid complete dissolution of lipids in ethanol. The spray-dried mannitol or LMH in various 158 
ratios were dispersed in the ethanolic solution followed by sonication for 15 min to break up any 159 
agglomerates of the carbohydrate particles before performing spray drying using the same Buchi B-160 
290 Mini Spray Dryer equipment, but this time connected with the Buchi’s inert loop system (Buchi, 161 
Switzerland). The homogeneity of the resultant alcoholic mixture was maintained by continuous 162 
stirring while feeding the mixture into the spray drier. The spray drying conditions were optimized 163 
by adjusting the inlet temperature at 120°C, spray flow rate was 600 L/h, feed rate was 11% and the 164 
outlet temperature was 73 ± 3°C. The resultant powder constituting lipid/carbohydrate was collected 165 
and referred to as ‘proliposomes’, which were stored in a desiccator for later use in the same day. 166 
 167 
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2.2.3 Hydration of spray-dried powder  168 
Samples of spray-dried powders were hydrated by adding deionized water followed by vortex mixing 169 
for 2 min in order to test for the possible generation of liposomes. The liposome dispersion was 170 
allowed to “anneal” for around 1 h at room temperature before performing further characterization. 171 
Allowing the liposomes to anneal at temperatures above that of the lipid phase transition (Tm) may 172 
promote the stability of liposomes by overcoming structural defects of the bilayers [29]. 173 
 174 
2.2.4 Product yield estimation  175 
The product yield (PY) of spray-dried powders was determined using the weight of the final spray-176 
dried powder (W₀) divided by the initial weight of carrier, lipid and drug employed (WT). The product 177 
yield, drug recovery and content drug uniformity were determined according to the following 178 
equations (30): 179 
𝑃𝑌 (%) =
𝑊°
𝑊𝑇
× 100                               𝐸𝑞. 1 180 
 181 
𝐷𝑟𝑢𝑔 𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑦 (%) =
𝑃𝑤
𝑊𝑇
× 100                               𝐸𝑞. 2 182 
Where Pw is the practical weight of the drug after spray-drying was performed, as quantified using 183 
high performance liquid chromatography (HPLC). 184 
𝐶𝑜𝑛𝑡𝑒𝑛𝑡 𝑑𝑟𝑢𝑔 𝑢𝑛𝑖𝑓𝑜𝑟𝑚𝑖𝑡𝑦 (%) =
𝐷𝑟𝑢𝑔 𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑦 (%)
𝑃𝑌 (%)
× 100                              𝐸𝑞. 3 185 
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 186 
2.2.5 Scanning electron microscopy (SEM) 187 
Particle size and morphology of spray-dried formulations were studied using scanning electron 188 
microscopy (SEM, Quanta-200, FEI at 20 kV). Spray-dried particles were spread onto an aluminium 189 
stub and coated with a film of gold using the JFC-1200 Fine Coater (JEOL, Tokyo, Japan).  190 
 191 
2.2.6 X-ray powder diffraction (XRPD) studies 192 
X-ray diffraction (XRPD) studies of powder were performed by utilizing the Equinox 2000 (Inel, 193 
France) using a diffracted-beam monochromator with Cu radiation. The intensity of diffractions was 194 
recorded at an angle of 2-theta, at a diffraction scan duration of 20 min. The experiments were 195 
conducted by keeping the voltage at 32 kV and the current generator at 28 mA. 196 
 197 
2.2.7 Studies of vesicle morphology using transmission electron microscopy (TEM)  198 
A drop of hydrated spray-dried powder was carefully positioned on carbon-coated copper grids (400 199 
mesh; TAAB Laboratories Equipment Ltd., UK), followed by negative staining (using 1% 200 
phosphotungstic acid; PTA). The samples were imaged using the Philips CM 120 Bio-Twin electron 201 
microscope (Philips Optics BV, the Netherlands). 202 
 203 
2.2.8 Particle size measurements of hydrated samples  204 
Size and size distribution of liposomes generated upon hydration of spray-dried proliposomes were 205 
analysed by laser diffraction using the Mastersizer 2000 (Malvern Instruments Ltd., UK). The median 206 
size, also referred to as volume median diameter (VMD; 50% undersize), and Span were measured 207 
to represent the size and size distribution (polydispersity) of liposomes, respectively. Span value 208 
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represent the difference between 90% undersize and 10% undersize divided by the VMD. Span is a 209 
unit-less term introduced by the manufacturer of the Malvern Mastersizer 2000 instrument. 210 
 211 
2.2.9 Zeta potential measurements 212 
The zeta potential of vesicles was determined via the Zetasizer Nanoseries instrument (Malvern 213 
Instruments Ltd., UK) by choosing the relevant software option of the instrument. Proliposomes were 214 
hydrated with deionized water with shaking. The resultant liposomes  (70 μL) were loaded via a 215 
Gilson pipette into the Malvern’s zeta potential cells, after setting the temperature at 25°C and 216 
allowing 2 min for sample equilibration in order to obtain consistent zeta potential measurements. 217 
 218 
2.2.10 Drug content and entrapment efficiency (EE) studies  219 
Spray-dried powder (10 mg) was dispersed with deionized water (1 mL) to generate liposomes. The 220 
dispersion was transferred into a volumetric flask (10 mL), and methanol (1 mL) was added to 221 
dissolve the lipid followed by making up the volume with water. HPLC was employed to determine 222 
the drug content in the flask (i.e. total drug loaded into the 10 mg powder sample) by adapting a 223 
method we published established (13). The mobile phase was made by making a buffer solution 224 
constituting a mixture of sodium hexane sulfonate in water (5 mM) and methanol (75:25 v/v), to 225 
which glacial acetic acid was added to have 1% of the total volume. The high-performance liquid 226 
chromatography (HPLC; Agilent 1200 - UV detector system; Hewlett-Packard Co., USA) was set up 227 
with a Symmetry C-18 column (150 mm, 4.6 mm, 5m; Waters, UK). The samples (injection volume 228 
of each is 20 µL) were analysed at 276 nm. The flow rate of mobile phase was set up at 1 mL / min 229 
at 40 °C. To determine the entrapment efficiency (EE), spray-dried powder (10 mg) was hydrated 230 
using deionized water (50 µL) followed by vortex mixing for 2 min and dilution with deionized water 231 
(950 µL). The liposomes were left for 1 h at room temperature to anneal, followed by further dilution 232 
to 8 mL with deionized water. The liposomes were then centrifuged at 55,000 rpm (277,000 x g) for 233 
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35 min at 6°C (Beckman LM-80 ultracentrifuge; Beckman Coulter Instruments, USA). The 234 
supernatant was aspirated for subsequent analysis of SS (the unentrapped fraction of drug). The EE 235 
was determined using the following equation: 236 
 237 
𝐸𝐸(%) =
𝑇𝑜𝑡𝑎𝑙 𝑑𝑟𝑢𝑔 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 − 𝑈𝑛𝑒𝑛𝑡𝑟𝑎𝑝𝑒𝑑 𝑑𝑟𝑢𝑔
𝑇𝑜𝑡𝑎𝑙 𝑑𝑟𝑢𝑔 𝑙𝑜𝑎𝑑𝑖𝑛𝑔
× 100                𝐸𝑞. 4 238 
2.2.11. In vitro drug release study 239 
The release of SS from liposomes generated from the proliposome powders was investigated using 240 
the dialysis method. Spray-dried powder (71 mg containing 1 mg SS) was dispersed with deionized 241 
water (0.5 mL) followed by vortex mixing for 1 min and dilution with deionized water (1.5 mL) to 242 
generate liposomes. The dispersion was placed in a dialysis tube (MWCO 3500) and tightly sealed. 243 
For free drug, 1 mg SS was dissolved in 1 ml of ethanol: water: tween 80 (20:79.9:0.1%). Then, the 244 
dialysis tube was immersed in 50 mL (total volume) release medium (deionized water) containing 245 
0.1% (v/v) Tween 80) and incubated with stirring in for 24 h at 37°C. Samples (0.3 mL) were taken 246 
at time intervals from the release medium for 24 h, and replaced by a similar volume of fresh medium. 247 
The concentration of SS was determined by HPLC using the methods described above. 248 
 249 
2.2.12 Assessment of aerosol performance in vitro  250 
Using the Two-Stage Impinger (TSI), also called the Twin Impinger or the Single Stage Glass 251 
Impinger (Copley Scientific Ltd, Nottingham, UK), the performance of spray-dried proliposome 252 
aerosols and deposition profile were investigated (31) using a Miat Monodose powder inhaler (Miat, 253 
Italy). TSI is designed with two stages: the upper stage (S1) and the lower stage (S2), attempting to 254 
represent the upper airways and lower airways, respectively. The flow rate through the TSI was set 255 
up at 60 L/min. The cut-off aerodynamic diameter between the two stages at 60 L/min is 6.4 µm, 256 
hence particles smaller than this aerodynamic diameter will most likely deposit in the lower impinger 257 
and will constitute the ‘fine particle fraction’ (‘FPF’) (31). Proliposome powder (25 mg) was filled 258 
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into hydroxypropyl methylcellulose (HPMC; size 3) capsules. Each capsule was loaded into the Miat 259 
device which was then connected to the impinger that contained deionized water as collection 260 
medium (7 mL in the upper stage (S1) and 30 mL in the lower stage (S2). In each experiment, the 261 
capsule content was pulled by applying negative pressure (60 L/min) through the actuated inhaler 262 
device over 5 s. Then, the impinger was dismantled and each stage, the inhaler device and capsule 263 
were separately rinsed with deionized water for subsequent drug quantification using HPLC. The 264 
total amount of drug in the inhaler device, S1 and S2 constitutes the recovered dose (RD) of the drug. 265 
The amount of drug deposited in S1 and S2 of the impinger constitutes the emitted dose (ED) 266 
calculated as the percentage proportion of the RD (Eq. 5). The percentage proportion of the drug that 267 
is deposited in S2 of the impinger was calculated as the “FPF” (Eq. 6). 268 
𝐸𝐷 =
𝑆1 + 𝑆2
𝑅𝐷
× 100                       𝐸𝑞. 5 269 
𝐹𝑃𝐹 =
𝑆2
𝑅𝐷
× 100                               𝐸𝑞. 6 270 
 271 
2.2.13 Proliposome flowability studies  272 
Aiming to understand the behaviour of selected formulations, the bulk density of the spray-dried 273 
proliposome powder was measured by using the ERWEKA tapped density meter (ERWEKA®p 274 
Gmbh, D-63150 Heusenstamm, Germany). A defined mass of powder was poured into a calibrated 275 
measuring cylinder and the volume occupied by the powder was recorded. The tapped density of 276 
spray dried powder was determined by volume measurement of the tapped mass until no further 277 
changes in the powder volume were observed. Hausner ratio and Carr‘s index, also called Carr’s 278 
compressibility index, for each spray dried powder were derived according to the following 279 
equations: 280 
𝐵𝐷 =
𝑊
𝑉
× 100                       𝐸𝑞. 7 281 
𝑇𝐷 =
𝑊
𝑉𝑡
                       𝐸𝑞. 8 282 
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𝐻𝑎𝑢𝑠𝑛𝑒𝑟 𝑅𝑎𝑡𝑖𝑜 =
𝑉
𝑉𝑡
                       𝐸𝑞. 9 283 
𝐶𝑎𝑟𝑟′𝑠 𝐼𝑛𝑑𝑒𝑥 = [1 − (
𝐵𝐷
𝑇𝐷
)] × 100                       𝐸𝑞. 10 284 
Where BD and TD are bulk density and tapped density, respectively, and V and Vt are actual volume 285 
and tapped volume, respectively. 286 
 287 
2.2.14 Statistical analysis 288 
All experiments were conducted three times using three different proliposome batches. Statistical 289 
significance was studied using one-way analysis of variance (ANOVA) and student’s t-tests, for 290 
comparing more than two sets and two groups of results, respectively. P values < 0.05 indicate that 291 
difference between compared groups is statistically significant. 292 
 293 
3. Results and discussion 294 
3.1 Product yield and drug content uniformity of spray-dried proliposomes 295 
Table 2 shows the product yield (PY), drug recovery and drug content uniformity of powder 296 
formulations. Since spray-drying conditions were the same for all formulations, any difference in PY 297 
was attributed to formulation composition, namely, carrier type and lipid to carrier ratio. Spray-drying 298 
parameters such as atomizer design, flow rate and temperature of the drying air, solid content of the 299 
feed solution can all influence PY of spray-dried powder (32).  300 
For both carriers, a direct relationship was observed between PY and carrier concentration (Table 2). 301 
PY of F1 was lower than F2 (p˂0.05), and PY of F2 was lower than F3, F4 and F5 (p˂0.05) (Table 302 
2). However, when PY values of F3, F4 and F5 were compared, the difference was not significant 303 
statistically (P>0.05). Moreover, PY of F6 was significantly (p˂0.05) lower than PY of F7 which, in 304 
turn, was significantly (p˂0.05) lower than PY values observed with F8, F9 and F10. Only a trend of 305 
higher PY was also found for F9 and F10 when compared to F8 (p˃0.05) (Table 2). The decrease in 306 
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PY of spray-dried formulations is attributed to possible adherence of the sprayed droplets and dry 307 
particles to the inner walls of the drying compartment, or because of poor collection of fine powder 308 
by the cyclone separator [33]. Thus, the high lipid content of F1, F2, F6 and F7 can be responsible 309 
for the low PY of these formulations, causing adherence of lipid to the inner walls of the drying 310 
compartment.  311 
The PY of LMH formulations (F6, F7, F8, F9 and F10) was generally higher than PY of proliposomes 312 
based on mannitol carrier (F1, F2, F3, F4 and F5), indicating that it is not only lipid content that can 313 
affect PY but also carrier type (Table 2). Other reports have demonstrated that glass phase transition 314 
(Tg) of carbohydrates has a prime effect on the behaviour of formulations during spray drying (34-315 
37). When the temperature during spray drying is higher than Tg of the sugar employed, adherence 316 
of formulation components on the walls of the drying chamber may increase, resulting in lower 317 
powder yields (38). The Tg of lactose is 101
oC (39,40) which is higher than the outlet temperature 318 
used in the present study, whilst Tg of mannitol is lower than the outlet temperature used (41-44), 319 
making mannitol-based proliposomes more adhesive with concomitant lower PY than LMH-based 320 
formulations (Table 2). 321 
Table 2 also shows the recovery values of salbutamol sulphate (SS). The recovery of drug increased 322 
with increasing the carrier ratio in the proliposomes, regardless of carrier type. The enhanced drug 323 
recovery is paralleled with the higher PY obtained when higher carrier ratios (i.e. lower lipid 324 
concentrations) were used. Thus, low drug recovery for F1, F2, F6 and F7 formulations is attributed 325 
to the incorporation of high lipid contents. Table 2 also shows drug content uniformity in the spray-326 
dried proliposomes, which was in the range of 90 - 109%, indicating uniform distribution of SS in 327 
the powder. Drug content uniformity using LMH carrier was higher than formulations based on 328 
mannitol carrier (Table 2). In an attempt to provide the reasons behind these differences, particle 329 
morphology of proliposomes was investigated as illustrated in the subsequent section.  330 
 331 
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3.2 Morphology of spray-dried proliposome particles 332 
Particle morphology of proliposomes presented in Table 1 was studied using SEM (Figure 1). 333 
Mannitol-based particles looked spherical regardless of lipid to carrier ratio (Figure 1), coming in 334 
agreement with previous investigations employing this carrier (26). Particles of F1 and F2 were 335 
spherical and had small sizes, and apparently smooth surfaces, and tended to form large agglomerates 336 
(Figure 1a, b). The agglomeration of these two formulations can be attributed to their high lipid 337 
content, and may justify their low PY values (Table 2), making their potential for ‘deep lung’ 338 
deposition questionable. By contrast, F3 particles were small, porous and spherical, with less 339 
propensity to form agglomerates (Figure 1c). Porosity of particles can enhance their aerosol 340 
performance (45). F4 and F5 were small and spherical with apparently smooth surfaces and evidence 341 
of particle agglomeration (Figure 1d, e), possibly due to high surface energy of the particles, which 342 
commonly increases cohesiveness and compromises flowability (46-48).   343 
By contrast, LMH-based proliposome microparticles were irregular, rough and not similar in size 344 
(Figure 2). LMH is practically insoluble in ethanol used as the solvent in the present investigation. 345 
Upon atomization during spray drying, it appears that ethanol did not form uniform droplets; hence, 346 
the resultant proliposome particles had an irregular shape and wide size distribution. Studies have 347 
correlated particle surface morphology with aerosol performance (49). Smooth particles have high 348 
flowability and are potentially applicable for aerosolization (50). The irregular shape and rough 349 
surface of lactose microparticles can promote the interaction between carrier and drug (49).  350 
Particles that have spherical shape may have high chance for deposition in the peripheral airways, 351 
especially when the aerodynamic size is in the range of 1-5 µm (51-54). Thus, LMH-based 352 
proliposomes might have lower suitability for delivery from DPI devices than mannitol-based 353 
formulations, since LMH-based particles are larger and more irregular in shape (Figure 2). According 354 
SEM, the potentially most appropriate proliposome formulation for use as DPIs would be F3 (i.e. 355 
using mannitol carrier with 1:6 w/w lipid to carrier ratio) (Figure 1c). 356 
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 357 
3.3 Crystallinity of spray-dried formulations 358 
XR diffraction profiles of SS are shown in Figure 3. The intensity of drug peaks before and after 359 
spray drying indicates that the crystalline characteristics of SS were preserved. The intensity peak 360 
after spray drying increased slightly, because ethanol can increase powder crystallinity (55-58). 361 
Mannitol had high crystallinity before spray drying (Figure 3c); however, the peak intensity decreased 362 
by spray drying (Figure 3d), indicating reduced crystallinity of this sugar (59). High amorphous 363 
content of solids can facilitate dispersion of powder in aqueous media (60-62), which is advantageous 364 
in dry powder formulations. 365 
Spray-dried mannitol is crystalline (Figure 3d). The X-ray diffraction profile of the drug was not 366 
detected in the proliposome formulations (Figure 4; Figure 6), because of the low drug concentration 367 
when compared to the other formulation components (i.e. mannitol and lipid). Moreover, the drug 368 
might have been coated by SPC that is known to be amorphous, resulting in poor detection of 369 
crystalline drug traces. Similarly, DSC curve of the formulation F3, for example, did not show a 370 
thermogram for the drug. However, the pure drug shows an endothermic melting peak with the onset 371 
of about 200ºC. 372 
The X-ray diffraction patterns of mannitol proliposomes are presented in Figure 4. The crystalline 373 
characteristics of mannitol were dominant in all formulations because of the high content of sugar 374 
compared to the other components of the formulations (i.e. drug and lipid). X-ray diffraction profile, 375 
as evident from the intensity of the main peak of mannitol-based proliposomes was formulation-376 
dependent, when F1-F5 formulations were considered. The intensity of the main peak increased 377 
slightly by increasing the ratio of mannitol, owing to the high crystallinity of this type of sugar. The 378 
intensity peak of mannitol-based proliposomes (F1-F5) was lower than mannitol alone, indicating 379 
other formulations components (mainly the lipid) have decreased powder crystallinity.  380 
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Figure 5 shows the X-ray diffraction profiles of LMH before and after spray-drying in aqueous or 381 
alcoholic solutions. As shown in Figure 5a, LMH demonstrated a crystalline profile before spray-382 
drying (Figure 5a), and converted into amorphous because of spray-drying in aqueous solution 383 
(Figure 5b), agreeing with previous reports employing this type of sugar (63-67). By contrast, LMH 384 
preserved its crystallinity after spray drying from its ethanolic solution, possibly because of the lower 385 
solubility of this sugar in ethanol when compared to its aqueous solubility. However, the intensity 386 
peak of LMH was diminished by spray drying from ethanol compared to before spray drying (Figure 387 
5c). LMH is crystalline in all formulations due to the high sugar content, regardless of formulation 388 
(Figure 6); however, slight differences in the intensity of the main peak was observed when the 389 
formulations F6-F10 were compared. Thus, crystallinity increased slightly with increasing LMH ratio 390 
in the formulation. 391 
The DSC thermographs for F3 and F8 conformed the preserved crystallinity of both mannitol and 392 
LMH, respectively, after spray-drying from ethanolic solution. However, no peaks appeared for the 393 
drug in both formulations thermograms (data not shown).  394 
3.4 Drug entrapment in liposomes generated upon hydration of spray-dried proliposomes  395 
Drug entrapment efficiency (EE) in liposomes was determined after hydration of the proliposome 396 
powder (Table 3). For mannitol-based proliposomes, entrapment differed slightly for different 397 
formulations (Table 3). This can be attributed to different proportions of lipid recovered after spray 398 
drying, or difference in morphology of proliposome microparticles with accordance to using different 399 
formulations. Rough carrier particle surfaces may facilitate carrier-drug interactions due to having 400 
high surface area, whilst smooth surfaces may result in loose interactions between the drug and carrier 401 
(49,68,69). Thus, the apparently rough surfaces of LMH-based formulations could be responsible for 402 
enhanced drug-carrier interactions, facilitating drug encapsulation by liposomes upon hydration. This 403 
explains the higher drug entrapment in vesicles generated upon hydration of LMH-based 404 
proliposomes compared to mannitol-based formulations (Table 3). Furthermore, F6 and F7 (i.e. lower 405 
LMH content; higher lipid proportion) had greater drug entrapment efficiencies than F8-F10 (i.e. 406 
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higher LMH content; lower lipid content) formulations. Thus, the relatively low lipid concentrations 407 
in F8, F9 and F10 caused the generation of dilute liposome dispersions; thus, lower drug proportions 408 
were encapsulated by the vesicles (Table 3). LMH-based proliposomes with 1:2 lipid to carrier ratio 409 
(i.e. F6 formulation) gave the greatest drug entrapment efficiency, because of the high lipid content 410 
in this formulation. These findings demonstrated a correlation between PY, particle morphology and 411 
drug entrapment efficiency. Other investigators have hypothesized possible hydration of proliposome 412 
powders in situ within the lung after inhalation by exploiting the aqueous physiological environment 413 
of the lung (24-28). In vivo investigations are merited in the future to explore the validity of this 414 
hypothesis. Our ongoing studies involving the use of simulated lung fluids to explore the potential of 415 
dehydrated liposome and proliposome formulations when the hydration environment is made from 416 
aqueous systems other than simple solutions are supportive to the aforementioned hypothesis (results 417 
unpublished).       418 
 419 
3.5 Size analysis of hydrated proliposomes 420 
The volume median diameter (VMD), also referred to as median size, of liposomes after 421 
reconstitution of the powders in deionized water was in the range of 3.38 - 6.01 µm and 3.23 - 5.96 422 
µm for mannitol-based vesicles and LMH-based liposomes, respectively (Table 3). Liposome size is 423 
an influential factor on drug entrapment, retention time of the vesicle components in the lung, and 424 
drug release profile (70). F1 and F6 had the largest VMD measurements and highest drug entrapment 425 
efficiencies, whilst F4 and F10 had the smallest VMD values and lowest drug entrapment 426 
measurements (Table 3). The high lipid content in F1 and F6 could be responsible for generating the 427 
largest vesicles that demonstrated the highest drug entrapment efficiencies. Drug release and 428 
absorption of liposome-encapsulated drug are influenced by liposome size and lipid phase 429 
composition. For instance, the localized time of terbutaline in the pulmonary system was prolonged 430 
by enriching the liposome formulations with CH or by using phospholipids with saturated alkyl chains 431 
(71). Large liposomes and multilamellarity can promote drug entrapment and prolong drug release in 432 
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the lung (72). The Span measurements were approximately 2 or less except for F4, F8 and F9 (Table 433 
3), indicating different polydispersity for different formulations. The high Span values (i.e. 434 
polydispersity) could be due to aggregation of liposomes.    435 
 436 
3.6 Zeta potential measurements  437 
Particles with a net surface charge (negative or positive) may repel each other, causing lower tendency 438 
for aggregation during storage, which improves physical stability of formulation stability (73). 439 
Furthermore, surface charge on particles, especially negative charge, may influence the interaction of 440 
particles with biological membranes (74-76). Liposomes in all formulations had very slightly negative 441 
zeta potential values (Table 3), indicating that lipid to carrier ratio, and carrier type did not affect the 442 
surface charge of vesicles. These findings support the potential of our liposome formulations, as 443 
particles with negative charge may demonstrate enhanced cellular uptake (74-76). 444 
 445 
3.7 Studies of vesicle morphology using transmission electron microscopy (TEM)  446 
Liposomes generated upon hydration of mannitol-based proliposomes were a mixture of large 447 
unilamellar (LUVs) and oligolamellar vesicles (OLVs), while structures generated from LMH-based 448 
powders were rich of vesicle clusters and “worm-like” shapes (Figure 7). These findings are in 449 
agreement with one of our previous investigations, for liposomes generated from LMH-based 450 
proliposomes manufactured using a modified rotary evaporator (77). Based on this TEM study, 451 
liposome morphology was unaffected by other formulation factors such as lipid to carrier ratio or 452 
lipid composition. The slow dissolution of carrier, may slow the hydration of lipid, resulting in 453 
retarded deaggregation of vesicles and formation of elongated bilayer structures (77). By contrast, 454 
mannitol-based proliposomes may have better dispersion properties in water, which might be due to 455 
the small size, smooth surfaces and spherical shape of mannitol-based particles, as shown earlier by 456 
SEM (Figure 1), causing formation of spherical LUVs and OLVs (Figure 7). Thus, the different in 457 
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hydration patterns of phospholipid because of using proliposomes with different morphologies 458 
resulted in generation of vesicles with different morphologies (Figure 7). Interestingly, previous 459 
studies employing traditional proliposomes manufactured using modified rotary evaporators revealed 460 
instant generation of liposomes upon hydration of proliposomes under static conditions (i.e. without 461 
shaking) via the ‘budding off’ mechanism (22, 23, 77). Further studies should investigate the role of 462 
carrier type on the behaviour of liposomes generated from proliposomes.   463 
  464 
3.8 Powder aerosolization performance in vitro 465 
Proliposome with spherical shapes would be expected to have better flowability, and when combined 466 
with having small particle size (i.e. in the ‘respirable’ range), they become likely to deposit in the 467 
lower airways. However, SEM used to evaluate particle morphology does not give information about 468 
aerodynamic size. The deposition site of inhaled particle in the pulmonary system is influenced by 469 
particle shape and aerodynamic size (78). For this reason, inertial impaction studies using the two-470 
stage impinger (TSI) were conducted. Using the MIAT inhaler device, deposition of proliposome 471 
particles in the stages of the TSI was studied, in order to determine the recovered dose (RD), emitted 472 
dose (ED) and ‘FPF’ (Figure 8).  473 
Figure 8 shows that the performance of proliposome aerosols was dependent on carrier type and lipid 474 
to carrier ratio (Figure 8). The RD for all formulations approached 100% (95.62 – 99.79%), with 475 
higher values for LMH-based proliposomes than mannitol-based formulations (p˂0.05)However, the 476 
delivery of coarse LMH-based proliposome particles from the capsule was better (i.e. ED was higher) 477 
than ED of mannitol-based proliposomes.  478 
The ED was high for all formulations (77.46 – 94.59%). However, LMH-based proliposomes had 479 
higher deposition in the upper stage (S1) of the impinger (i.e. lower ‘FPF’). These findings are in 480 
agreement with the earlier SEM studies, since all LMH-based proliposome formulations (F6-F10) 481 
(shown to have large sizes and irregular shapes; Figure 2) had extremely poor ‘FPF’ (0 - 3.99%) 482 
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(Figure 8). By contrast, mannitol-based microparticles were smaller and more spherical (Figure 1). 483 
Hence, they offered much greater ‘FPF’ (2.79 - 52.14%) compared to LMH-based powder. Particles 484 
having size of 1-5μm are likely to reach the peripheral airways following inhalation (51). F1 had the 485 
lowest FPF amongst mannitol formulations, which can be ascribed to particle agglomeration due to 486 
the high lipid content of this formulation. For F2 and F5, the ‘FPF’ values were 33.57 and 33.63%, 487 
respectively. These values were lower than those determined for F3 and F4, which can be attributed 488 
to the agglomeration occurring in F2 and F5 formulations because of the presence of small particles. 489 
By contrast, the lower agglomeration tendency of F3 and F4 might be responsible for the enhanced 490 
deposition of particles into the lower stage of the TSI (Figure 8). The subsequent section elaborates 491 
on studying the characteristics of proliposomes and the generated liposomes, using two distinguished 492 
formulations with superior aerosol performance.  493 
 494 
3.9. Additional powder characterization and drug release studies 495 
Further powder characterization studies and drug release investigations were conducted on best 496 
performing proliposome formulations, mainly relaying on the aerosol performance findings of the 497 
powders (Figure 8). Proliposome powders exhibited their best performance in terms of ‘FPF’ when 498 
the lipid to carrier ratio was 1:6; thus F3 (mannitol-based proliposomes) and F8 (LMH-based 499 
proliposomes) were further investigated in terms of powder flowability and moisture content, and the 500 
release profile of SS from the subsequently generated liposomes. Upon reflection on the earlier 501 
findings in this study, it was further observed that F3 and F8 formulations exhibited desirable 502 
characteristics in terms of drug recovery, PY and drug content uniformity (Table 2). Moreover, as 503 
observed earlier with SEM studies, F3 proliposomes were spherical and apparently smooth with low 504 
agglomeration propensity (Figure 1c), justifying the superior aerosol performance of this formulation 505 
(Figure 8) and supporting the rationale behind conducting flowability and drug release studies on this 506 
particular proliposome composition.  507 
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Accordingly, flowability studies were conducted on both F3 (as representative for mannitol-based 508 
proliposomes) and F8 (as representative for LMH-based formulations). Spray-dried powders of 509 
mannitol and LMH were used for comparison with the proliposome formulations to investigate the 510 
effect of lipid on powder flowability (Table 4). Flowability was assessed using Carr’s compressibility 511 
index and Hausner ratio according to the reference published in 1965 (79) and summarized in Table 512 
4.  Lipid-free carriers (i.e. spray-dried powders of mannitol or LMH) exhibited ‘Fair’ flowability 513 
according to both Hausner ratio and Carr’s index (Table 4; Table 5). When these carriers were used 514 
to manufacture spray-dried proliposomes (i.e. F3 as a representative for mannitol-based formulations, 515 
and F8 as a representative for LMH-based formulations), the flow characteristics were markedly 516 
compromised, so that F3 exhibited ‘Poor’ flowability, whilst F8 was regarded to have ‘Very very 517 
poor’ flowability according to both Hausner ratio and Carr’s index (Table 4; Table 5). Although the 518 
flowability findings do not look encouraging for both proliposome formulations (F3 or F8), the 519 
emitted dose (ED) of SS from the capsules to the impinger was considerably high, exceeding 80% 520 
(Figure 8), indicating that the ‘inspiratory’ flow rate through the impinger was sufficiently powerful 521 
to pull the proliposome powders from the inhaler device. However, the relatively better flow 522 
characteristics of F3 (Table 5) in addition to the spherical morphology, the relatively small physical 523 
size, and apparent smooth surfaces of this formulation (Figure 1c) were the prime reasons for the 524 
superior ‘FPF’ value observed for F3 (Figure 8). By contrast, F8 demonstrated very poor ‘FPF’ 525 
(Figure 8), possibly due to the relatively large size, irregular shape and rough surfaces (Figure 2c) 526 
and the extremely poor flow properties of the particles (Table 5). The flow rate through the impinger 527 
was appropriate to aspirate a large dose of F8 particles, but most of the drug dose was deposited in 528 
the upper impinger, resulting in extremely poor ‘FPF’ values (Figure 8). Particle surface morphology 529 
can influence aerosol performance (49) and smooth particles may exhibit better aerosolization 530 
characteristics (50). It is worth to mention that the residual moisture contents for both formulations 531 
F3 and F8 were less than 0.8% as determined by thermogravimetric analysis (TGA) at 110oC (data 532 
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not shown). TGA is a well-established analytical tool for the determination of residual moisture 533 
content in powdered formulations and solid excipients (80, 81). 534 
When the in vitro drug release profiles of F3 and F8 were compared, the difference was insignificant 535 
for most intervals studied (p ˃0.05); however, a trend for faster drug release was observed with the 536 
F3 formulation (Figure 9). After 24 h, the cumulative release for SS was 79% and 72% for F3 and F8 537 
formulations, respectively, demonstrating advantageous sustained release for both formulations in 538 
comparison to the free SS which demonstrated 93% cumulative release after as short as 8 h and full 539 
release after 24 h (Figure 9). The drug release findings of F3 and F8 indicate that carrier type 540 
(mannitol or LMH) had no significant influence on the drug release profile.   541 
 542 
In our opinion, if nebulizable liposome formulations like Arikace® are considered the first generation 543 
of inhalable liposome medicines, liposomal and proliposomal DPIs might constitute the second-544 
generation formulations. The proliposome formulations introduced in this study offer the rationale of 545 
delivering small therapeutic doses of SS with relatively small doses of phospholipid and sugar; this 546 
may reduce the risk of ‘overwhelming’ the lung with large amounts of exogenous lipids. Future 547 
investigations should expand to explore the role of materials used to manufacture the capsules that 548 
accommodate the powder prior to loading into the inhaler device (82), and the role of inhaler device 549 
design (83, 84), aiming to maximize formulation output and FPF. Importantly, aerosol flow rate 550 
from DPI devices may affect the deposition profile for conventional powders (85); thus, studying 551 
the role of flow rate through an impinger and its influence on the emitted dose and FPF is part of our 552 
ongoing investigations using phospholipid-based powders. Finally yet importantly, in vivo studies 553 
using experimental animals are needed in the future to further explore the potential of DPI 554 
proliposomes for inhalation to treat pulmonary diseases (e.g. asthma). 555 
 556 
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4. Conclusions 557 
In this study, novel spray-dried proliposome formulations for delivery as dry powders were 558 
investigated using LMH or mannitol as carriers and SPC and CH as lipid composition. The ratio of 559 
carrier to lipid has influenced the product yield, particle morphology, and powder crystallinity and 560 
deposition pattern in the TSI. The characteristics of proliposome microparticles have accordingly 561 
influenced the vesicles generated, in terms of size, surface charge and drug entrapment. The 562 
production yield of spray-dried LMH formulations was higher than the yield values shown for 563 
mannitol-based proliposomes. X-ray diffraction patterns demonstrated the crystallinity of 564 
proliposomes after spray drying from ethanolic suspensions, indicating interaction between the 565 
proliposome constituents. SEM, impinger investigations, and powder floewability studies showed 566 
mannitol to be a more appropriate carrier for manufacturing DPI proliposome formulations because 567 
its particles were spherical, smooth and small after spray drying, and offered higher ‘FPF’ using the 568 
TSI (exceeding 50%). By contrast, LMH-based proliposomes were irregular in shape, had rough 569 
surfaces, larger sizes and poorer flowability, compromising its suitability for as DPI formulations. 570 
However, the vesicles generated upon hydration of proliposomes using LMH carrier offered higher 571 
drug entrapment efficiencies. The higher drug entrapment in liposomes generated from LMH-based 572 
formulations can be ascribed to the larger size of vesicles generated using this carrier. The zeta 573 
potential values were slightly negative, regardless of formulation composition. Moreover, TEM 574 
showed that mannitol-based proliposomes generated spherical vesicles, while bilayer structures 575 
generated upon hydration of LMH-based proliposomes were “worm-like” clusters. Following on the 576 
advanced development stages achieved by nebulizable liposome dispersions for inhalation, we expect 577 
phospholipid-based dry powders delivered via DPI devices, similar to the formulations developed in 578 
this study, to constitute the second generation of inhalable liposomes.  579 
 580 
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Table 1: Composition of the proliposome formulations manufactured using spray drying  797 
Formulation Lipid : Carrier 
(w/w) 
Lipids (SPC:CH; 1:1) 
(mg) 
Mannitol 
(mg) 
LMH 
(mg) 
SS 
(mg) 
F1 1:2 100 200 - 10 
F2 1:4 100 400 - 10 
F3 1:6 100 600 - 10 
F4 1:8 100 800 - 10 
F5 1:10 100 1000 - 10 
F6 1:2 100 - 200 10 
F7 1:4 100 - 400 10 
F8 1:6 100 - 600 10 
F9 1:8 100 - 800 10 
F10 1:10 100 - 1000 10 
 798 
  799 
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Figure 1: SEM images of mannitol-based proliposomes: (a) F1, (b) F2, (c) F3, (d) F4 and (e) F5 805 
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Figure 2: SEM images of LMH-based proliposome formulations: (a) F6, (b) F7, (c) F8, (d) F9 and (e) 810 
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 816 
Figure 3: X-ray powder diffraction of SS (a), mannitol (c) prior to spray-drying, and SS (b), mannitol 817 
(d) after spray-drying in ethanolic suspension 818 
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 832 
 833 
 834 
Figure 4: X-ray powder diffraction profiles of mannitol-based proliposomes: (a) F1, (b) F2, (c) F3, (d) 835 
F4 and (e) F5 836 
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 842 
 843 
Figure 5: X-ray powder diffraction profiles of LMH: (a) prior to spray-drying, (b) after spray-drying 844 
from its aqueous solution and (c) after spray-drying from its ethanolic suspension 845 
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 860 
Figure 6: X-ray powder diffraction profiles of LMH-based proliposomes: (a) F6, (b) F7, (c) F8, (d) F9, 861 
and (e) F10 862 
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 865 
 866 
Figure 7: TEM of (a) OLV liposomes generated upon manual hydration of mannitol-based proliposomes 867 
and (b) elongated worm-like bilayer liposomes and liposome clusters generated from LMH-based 868 
proliposomes using 1:6 w/w lipid to carrier 869 
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 874 
Figure 8: Recovered dose (RD; %), emitted dose (ED; %) and ‘fine particle fraction’ (‘FPF’; %) of 875 
mannitol-based and LMH-based proliposomes (n = 3 ± SD) 876 
 877 
 878 
 879 
 880 
 881 
 882 
 883 
 884 
 885 
 
 
Spray-dried proliposomes for aerosol delivery 
40 
 
 886 
Figure 9: Drug release profile from liposomes generated from mannitol-based proliposomes 887 
(F3) and LMH-proliposomes (F8) in comparison to free SS (n = 3 ± SD) 888 
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